Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis
Biogen Inc. (BIIB)
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
biogen.com/en_us/investors.html
Company Research
Source: GlobeNewswire
Evidence supports potential of serum neurofilament light (sNfL) as clinically useful biomarker in MS; Biogen and Siemens Healthineers collaborate to develop sNfL blood testReal-world data add to the large body of evidence establishing the long-term effectiveness of TECFIDERA and TYSABRI, including in newly diagnosed patientsMS PATHS, generating standardized data from more than 13,000 people with MS, uses new tools to objectively monitor for cognitive changes CAMBRIDGE, Mass., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Through its research initiatives, Biogen Inc. (Nasdaq: BIIB) aims to identify new ways to manage and monitor multiple sclerosis (MS) disease progression and provide physicians with real-world evidence to help inform treatment decisions. Data show serum neurofilament light (sNfL) is a potential biomarker of disease activity and treatment response, and results from MS PATHS (Multiple Sclerosis Partners Advancing Technology and Health Solutions) support the use of technology to b
Show less
Read more
Impact Snapshot
Event Time:
BIIB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIIB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
News
- Alzheimer's Therapeutics Market Size Expected to Surpass USD 8.18 Bn by 2032 [Yahoo! Finance]Yahoo! Finance
- Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at UBS Group AG from $250.00 to $214.00. They now have a "neutral" rating on the stock.MarketBeat
- Global Pulmonary Fibrosis Biomarkers Market Size To Exceed USD 6.1 Billion By 2033 | CAGR of 4.3% [Yahoo! Finance]Yahoo! Finance
- Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Bank of America Co. from $280.00 to $260.00. They now have a "neutral" rating on the stock.MarketBeat
- Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at JPMorgan Chase & Co. from $270.00 to $240.00. They now have a "neutral" rating on the stock.MarketBeat
BIIB
Earnings
- 2/14/24 - Miss
BIIB
Sec Filings
- 4/12/24 - Form PRE
- 4/3/24 - Form 4
- 4/3/24 - Form 4
- BIIB's page on the SEC website